Walmsley Under Pressure Over GSK’s Strategy
Activist Investor Preparing To Pounce
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.